{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:11:05Z","timestamp":1778231465549,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-025-03459-2","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:27:09Z","timestamp":1773336429000},"page":"2163-2181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD in Japan: An Interim Analysis of Post-Marketing Surveillance"],"prefix":"10.1007","volume":"43","author":[{"given":"Takashi","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"3459_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR)","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR). Washington DC: American Psychiatric Association Publishing; 2022."},{"issue":"1","key":"3459_CR2","doi-asserted-by":"publisher","first-page":"15020","DOI":"10.1038\/nrdp.2015.20","volume":"1","author":"SV Faraone","year":"2015","unstructured":"Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):15020.","journal-title":"Nat Rev Dis Primers"},{"issue":"10222","key":"3459_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0140-6736(19)33004-1","volume":"395","author":"J Posner","year":"2020","unstructured":"Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020;395(10222):450\u201362.","journal-title":"Lancet"},{"issue":"4","key":"3459_CR4","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1542\/peds.2014-3482","volume":"135","author":"R Thomas","year":"2015","unstructured":"Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994\u20131001.","journal-title":"Pediatrics"},{"key":"3459_CR5","unstructured":"National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. (NICE Guideline NG87) 2019. https:\/\/www.nice.org.uk\/guidance\/ng87."},{"key":"3459_CR6","volume-title":"Guidelines for diagnosis and treatment of attention-deficit\/hyperactivity disorders 5th edition [in Japanese]","author":"K Saito","year":"2022","unstructured":"Saito K, Iida J. Guidelines for diagnosis and treatment of attention-deficit\/hyperactivity disorders 5th edition [in Japanese]. Tokyo: Jiho; 2022."},{"key":"3459_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Package insert of Vyvanse\u00ae capsules, lisdexamfetamine mesilate [in Japanese] 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/."},{"issue":"10","key":"3459_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40265-018-0936-0","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE. Lisdexamfetamine dimesylate: a review in paediatric ADHD. Drugs. 2018;78(10):1025\u201336.","journal-title":"Drugs"},{"key":"3459_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/NDT.S9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"3459_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","volume":"36","author":"JC Ermer","year":"2016","unstructured":"Ermer JC, Pennick M, Frick G. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36(5):341\u201356.","journal-title":"Clin Drug Investig"},{"key":"3459_CR11","unstructured":"Donald J, Suma K. Pharmacokinetics of oral lisdexamfetamine dimesylate (LDX; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse. 2006. https:\/\/www.sec.gov\/Archives\/edgar\/data\/1288379\/000114036106009298\/ex99_1.htm"},{"issue":"13","key":"3459_CR12","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1517\/14656566.2014.934811","volume":"15","author":"T Banaschewski","year":"2014","unstructured":"Banaschewski T, Rothermel B, Poustka L. Evaluation of a head-to-head study of lisdexamfetamine dimesylate and atomoxetine. Expert Opin Pharmacother. 2014;15(13):1961\u20135.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"3459_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450\u201363.","journal-title":"Clin Ther"},{"issue":"10","key":"3459_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","volume":"23","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23(10):1208\u201318.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"3459_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jaac.2014.01.017","volume":"53","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647\u201357.e1.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"3459_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"3459_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/cap.2019.0076","volume":"30","author":"H Ichikawa","year":"2019","unstructured":"Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K. Phase II\/III study of lisdexamfetamine dimesylate in Japanese pediatric patients with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;30(1):21\u201331.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"3459_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L, the 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"7","key":"3459_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1017\/S1092852900016898","volume":"13","author":"RL Findling","year":"2008","unstructured":"Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. CNS Spectr. 2008;13(7):614\u201320.","journal-title":"CNS Spectr"},{"issue":"1","key":"3459_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/npr2.12091","volume":"40","author":"H Ichikawa","year":"2020","unstructured":"Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit\/hyperactivity disorder. Neuropsychopharmacol Rep. 2020;40(1):52\u201362.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"1","key":"3459_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/cap.2011.0088","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(1):11\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"3459_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40263-017-0443-y","volume":"31","author":"DR Coghill","year":"2017","unstructured":"Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: a phase IV, 2-year, open-label study in Europe. CNS Drugs. 2017;31(7):625\u201338.","journal-title":"CNS Drugs"},{"issue":"7","key":"3459_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1177\/1087054712468486","volume":"19","author":"TA Cassidy","year":"2015","unstructured":"Cassidy TA, Varughese S, Russo L, Budman SH, Eaton TA, Butler SF. Nonmedical use and diversion of ADHD stimulants among U.S. adults ages 18-49: a national internet survey. J Atten Disord. 2015;19(7):630\u201340.","journal-title":"J Atten Disord"},{"issue":"5","key":"3459_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/15563650.2015.1027903","volume":"53","author":"ME Kaland","year":"2015","unstructured":"Kaland ME, Klein-Schwartz W. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers. Clin Toxicol. 2015;53(5):477\u201385.","journal-title":"Clin Toxicol"},{"key":"3459_CR25","unstructured":"Takashi O, Masanori O, Hideo U, Kazuhiro T, Yoshimasa O, Kazuo M, et al. \u65e5\u672c\u4eba\u306e\u6ce8\u610f\u6b20\u9665\/\u591a\u52d5\u6027\u969c\u5bb3\u60a3\u8005\u306b\u304a\u3051\u308bmethylphenidate\u5869\u9178\u5869\u5f90\u653e\u9320\u306e\u9577\u671f\u6295\u4e0e\u6642\u306e\u6709\u52b9\u6027\u304a\u3088\u3073\u5b89\u5168\u6027\u2015\u2015\u5c0f\u5150\u671f\u306e\u9577\u671f\u4f7f\u7528\u306b\u95a2\u3059\u308b\u7279\u5b9a\u4f7f\u7528\u6210\u7e3e\u8abf\u67fb\u306e\u307e\u3068\u3081. Japan J Clin Psychopharmacol. 2013;16:715\u201328 (Japanese)."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03459-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03459-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03459-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:23Z","timestamp":1778229443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03459-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3459"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03459-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takashi Okada has received consultancy fees from Otsuka Pharmaceutical Co. Ltd and lecture fees from EA Pharma Co. Ltd, Janssen Pharmaceutical K.K., Lundbeck Japan K.K., Meiji Seika Pharma Co. Ltd, Merck Sharp & Dohme K.K., Nobelpharma Co. Ltd, Otsuka Pharmaceutical Co. Ltd, Shionogi & Co. Ltd., Sumitomo Pharma Co. Ltd, Takeda Pharmaceutical Co. Ltd, Viatris Pharmaceuticals Japan G.K., and Yoshitomi Pharmaceutical Industries Ltd. Hiroyuki Ida is an employee of Takeda Pharmaceutical Co. Ltd. Kouji Yamashita is an employee of Takeda Pharmaceutical Co. Ltd and owns Takeda stock. Kazuhiko Saito has received speaker fees from Shionogi & Co. Ltd and Takeda Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional Review Board and Ethics Committee approvals were not required for this post-marketing surveillance study according to the GPSP Ordinance. This study was conducted in accordance with the Declaration of Helsinki and in compliance with the Japanese Ministerial Ordinance on GPSP. Copyright licenses for the Clinical Global Impression\u2013Improvement (CGI-I) scale and the ADHD Rating Scale IV (ADHD-RS-IV) were obtained prior to their use in this study.\u00a0Patients\u2019 parent\/s or authorized legal guardian provided written informed consent for the collection and use of their data in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}